New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk
A newly released joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) recommends that healthy men who are screened regularly for prostate cancer and show no symptoms of the disease should talk to their doctors about using a 5-alpha reductase inhibitor (5-ARI) to prevent the disease. 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), which can contribute to the growth of prostate cancer. This guideline aims to provide a useful tool for clinicians and their patients in making an informed decision about the potential benefits and risks of taking 5-ARIs for preventing prostate cancer and examines the use of 5-ARIs as a method of "chemoprevention" for prostate cancer. Chemoprevention is the use of a natural, synthetic or biologic substance to reverse, suppress or prevent the development of cancer. Currently, 5-ARIs are used to treat other non-cancerous conditions, such as male-pattern baldness and benign prostatic hyperplasia.
Prostate cancer is the most common non-skin cancer among men and the second-leading cause of cancer death in men. "Although one in every six men in the United States will be diagnosed with prostate cancer, we are not recommending that all men take 5-ARIs," said Barnett S. Kramer, MD, MPH, Associate Director for Disease Prevention at the National Institutes of Health and co-chair of the guideline panel. "However, we would encourage men to begin a dialogue with their doctors to determine if they could benefit from taking 5-ARIs to reduce their prostate cancer risk."
The key recommendations in the guideline include:
- Men with a prostate-specific antigen (PSA) score of 3.0 or below who are screened regularly (or plan to get yearly PSA tests) and currently show no signs of prostate cancer are encouraged to talk with their doctor about the risks and benefits of taking a 5-ARI to further prevent their likelihood of getting prostate cancer
- Men who are already taking a 5-ARI for other conditions should talk to their doctor about continuing to use this drug for the prevention of prostate cancer
The ASCO/AUA recommendations on chemoprevention for prostate cancer are based on evidence gathered from clinical trials, including the Prostate Cancer Prevention Trial (PCPT), in which participating men took a 5-ARI for one to seven years. Trial data showed an overall relative risk reduction of approximately 25 percent in most men who took a 5-ARI to prevent prostate cancer.
"Although a large clinical trial has shown that 5-ARIs can decrease the incidence of prostate cancer, we are still not able to determine if the mortality from prostate cancer is reduced," said Paul F. Schellhammer, MD, a past president of the AUA and co-chair of the panel that developed the guideline. "However, the demonstrated effect of 5-ARIs in reducing prostate cancer incidence makes it reasonable to recommend them for use to prevent the disease. But, as with any drug, patients should discuss the risks and benefits with their physicians."
In conjunction with this guideline, ASCO developed a Decision Aid Tool, which uses straightforward charts and diagrams to explain the risks and benefits of 5-ARIs to patients and their families. One section, called "Thinking It Over," encourages patients to discuss potential treatment decisions with their doctors and their family and determine what risks and benefits matter most to them.
The guideline will be published in the March issue of the Journal of Clinical Oncology and the March issue of The Journal of Urology®. Along with the new guideline and the Decision Aid Tool, ASCO has released a corresponding patient guide available on ASCO's patient Web site, www.cancer.net.
Source: American Urological Association
- New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patientsTue, 26 Oct 2010, 10:54:36 EDT
- Mass screening for prostate cancer in Europe still not recommendedMon, 19 Apr 2010, 12:26:05 EDT
- Aspirin use associated with lower risk of cancer death for men with prostate cancerMon, 25 Oct 2010, 13:54:14 EDT
- MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men Mon, 4 Apr 2011, 9:34:32 EDT
- ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patientsThu, 2 Jun 2011, 17:36:14 EDT
Articles on the same topic
- Proepithelin encourages cell growth and migration in prostate cancerThu, 26 Feb 2009, 11:00:42 EST
- PSA levels accurately predict prostate cancer risk in African-American menTue, 24 Feb 2009, 13:43:36 EST
- Proepithelin encourages cell growth and migration in prostate cancerfrom Science CentricSun, 1 Mar 2009, 9:50:35 EST
- Drug recommended to prevent prostate cancer in some older menfrom LA Times - ScienceFri, 27 Feb 2009, 11:27:00 EST
- Drug recommended to prevent prostate cancer in some older menfrom LA Times - HealthFri, 27 Feb 2009, 11:25:24 EST
- Proepithelin encourages cell growth and migration in prostate cancerfrom PhysorgThu, 26 Feb 2009, 14:21:29 EST
- Proepithelin encourages cell growth and migration in prostate cancerfrom Science BlogThu, 26 Feb 2009, 11:25:00 EST
- Older Men Urged to Consider a Drug to Prevent Prostate Cancerfrom NY Times HealthWed, 25 Feb 2009, 18:56:03 EST
- PSA levels accurately predict prostate cancer risk in African-American menfrom Science CentricWed, 25 Feb 2009, 8:56:59 EST
- Doctors back wider consideration of prostate drugfrom PhysorgTue, 24 Feb 2009, 17:07:34 EST
- PSA levels accurately predict prostate cancer risk in African-American menfrom PhysorgTue, 24 Feb 2009, 13:42:20 EST
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Mars had oxygen-rich atmosphere 4,000 million years ago
- Outlook is grim for mammals and birds as human population grows
- The contribution of particulate matter to forest decline
- Scientists find new source of versatility so 'floppy' proteins can get things done
- An environmentally friendly battery made from wood
- Even with defects, graphene is strongest material in the world
- Detection of the cosmic gamma ray horizon: Measures all the light in the universe since the Big Bang
- Genetic engineering alters mosquitoes' sense of smell
- Allosaurus fed more like a falcon than a crocodile, new study finds
- 'Popcorn' particle pathways promise better lithium-ion batteries